Tag: AntiPD1

Replimune Presents Main Evaluation Information from IGNYTE Medical Trial of RP1 Mixed with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

Information from the IGNYTE main evaluation reveals clinically significant exercise throughout all subgroups, together with those that had obtained prior…

Business